CorMedix Inc. (CRMD): Price and Financial Metrics
GET POWR RATINGS... FREE!
CRMD POWR Grades
- Sentiment is the dimension where CRMD ranks best; there it ranks ahead of 77.57% of US stocks.
- CRMD's strongest trending metric is Momentum; it's been moving down over the last 177 days.
- CRMD ranks lowest in Quality; there it ranks in the 0th percentile.
CRMD Stock Summary
- For CRMD, its debt to operating expenses ratio is greater than that reported by just 7.56% of US equities we're observing.
- CRMD's price/sales ratio is 1,528.42; that's higher than the P/S ratio of 99.65% of US stocks.
- Revenue growth over the past 12 months for CORMEDIX INC comes in at -51.59%, a number that bests merely 4.12% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to CORMEDIX INC are CLPT, BNGO, OCX, LQDA, and HYPR.
- Visit CRMD's SEC page to see the company's official filings. To visit the company's web site, go to www.cormedix.com.
CRMD Valuation Summary
- CRMD's price/earnings ratio is -4.8; this is 120.69% lower than that of the median Healthcare stock.
- Over the past 157 months, CRMD's price/earnings ratio has gone down 0.6.
Below are key valuation metrics over time for CRMD.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CRMD | 2023-03-24 | 1530.4 | 2.5 | -4.8 | -3.3 |
| CRMD | 2023-03-23 | 1476.1 | 2.4 | -4.6 | -3.1 |
| CRMD | 2023-03-22 | 1444.6 | 2.4 | -4.5 | -3.0 |
| CRMD | 2023-03-21 | 1490.2 | 2.4 | -4.7 | -3.2 |
| CRMD | 2023-03-20 | 1534.8 | 2.5 | -4.8 | -3.3 |
| CRMD | 2023-03-17 | 1552.2 | 2.5 | -4.9 | -3.4 |
CRMD Growth Metrics
- Its 2 year net income to common stockholders growth rate is now at 36.19%.
- Its 2 year net cashflow from operations growth rate is now at -35.51%.
- Its 2 year cash and equivalents growth rate is now at 267.79%.
The table below shows CRMD's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 0.092103 | -24.07125 | -29.28374 |
| 2022-06-30 | 0.123374 | -23.57935 | -30.99939 |
| 2022-03-31 | 0.110312 | -21.20875 | -28.02748 |
| 2021-12-31 | 0.190936 | -21.15522 | -28.21023 |
| 2021-09-30 | 0.190254 | -21.21935 | -26.50618 |
| 2021-06-30 | 0.245186 | -23.02867 | -24.53757 |
CRMD's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CRMD has a Quality Grade of F, ranking ahead of 0.4% of graded US stocks.
- CRMD's asset turnover comes in at 0.004 -- ranking 418th of 682 Pharmaceutical Products stocks.
- ADAP, FBRX, and IDXX are the stocks whose asset turnover ratios are most correlated with CRMD.
The table below shows CRMD's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.004 | 0.132 | -5.939 |
| 2021-03-31 | 0.005 | 0.141 | -8.398 |
| 2020-12-31 | 0.007 | 0.144 | -6.360 |
| 2020-09-30 | 0.007 | 0.070 | -5.242 |
| 2020-06-30 | 0.006 | -0.103 | -3.741 |
| 2020-03-31 | 0.007 | -0.006 | -2.141 |
CRMD Price Target
For more insight on analysts targets of CRMD, see our CRMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $21.25 | Average Broker Recommendation | 1.5 (Moderate Buy) |
CRMD Stock Price Chart Interactive Chart >
CRMD Price/Volume Stats
| Current price | $4.14 | 52-week high | $8.02 |
| Prev. close | $4.14 | 52-week low | $2.64 |
| Day low | $4.00 | Volume | 377,100 |
| Day high | $4.32 | Avg. volume | 230,219 |
| 50-day MA | $4.02 | Dividend yield | N/A |
| 200-day MA | $3.90 | Market Cap | 170.91M |
CorMedix Inc. (CRMD) Company Bio
CorMedix Inc., a commercial pharmaceutical and medical device company, intends to in-license, develop, and commercialize prophylactic and therapeutic for the prevention and treatment of infectious and inflammatory diseases. The company was founded in 2006 and is based in Bridgewater, New Jersey.
Latest CRMD News From Around the Web
Below are the latest news stories about CORMEDIX INC that investors may wish to consider to help them evaluate CRMD as an investment opportunity.
CorMedix Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateConference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent business developments. Recent Corporate Highlights: C |
Cormedix Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update on March 30, 2023BERKELEY HEIGHTS, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2022, before the market opens on Thursday, March 30, 2023, and will host a corporate update conference call at 8:30am Eastern Time. T |
CorMedix Inc. Announces Regulatory and Manufacturing UpdatesBERKELEY HEIGHTS, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced updates related to the FDA compliance remediation activities at its primary contract manufacturing organization (“CMO”) and heparin active pharmaceutical ingredient (“API”) supplier, as well as updated timelines for potential |
CorMedix Inc. Announces Promotions in Commercial and Tech OpsBERKELEY HEIGHTS, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the following promotions within the organization: Erin Mistry, SVP Commercial, has been promoted to EVP and Chief Commercial Officer. Ms. Mistry will have oversight and responsibility for all commercial launch strategy for Defe |
Cormedix Inc. Announces Presentation at Conference Showing Mortality Risk and Complications in Patients Experiencing Catheter Related Blood Stream InfectionsBERKELEY HEIGHTS, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the abstract publication and poster presentation at the American Society of Health-System Pharmacists (ASHP) conference in Las Vegas, Nevada, December 4 – 8. The abstract being presented highlights research that was conducted b |
CRMD Price Returns
| 1-mo | -2.13% |
| 3-mo | -1.90% |
| 6-mo | 47.33% |
| 1-year | -25.81% |
| 3-year | 31.01% |
| 5-year | 360.00% |
| YTD | -1.90% |
| 2022 | -7.25% |
| 2021 | -38.76% |
| 2020 | 2.06% |
| 2019 | 12.87% |
| 2018 | 158.00% |
Continue Researching CRMD
Want to do more research on CorMedix Inc's stock and its price? Try the links below:CorMedix Inc (CRMD) Stock Price | Nasdaq
CorMedix Inc (CRMD) Stock Quote, History and News - Yahoo Finance
CorMedix Inc (CRMD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...